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Pntracoronary Fibrin-Specific
hrombolytic Infusion Facilitates Percutaneous
ecanalization of Chronic Total Occlusion
mr E. Abbas, MD, Stacy D. Brewington, MD, Simon R. Dixon, MBCHB, Judith A. Boura, MS,
indy L. Grines, MD, FACC, William W. O’Neill, MD, FACC
oyal Oak, Michigan
OBJECTIVES We sought to investigate the benefit, predictors of procedural success, and safety of
pre-procedural intra-coronary fibrin-specific lytic infusion (ICL) in patients with failed prior
percutaneous coronary intervention (PCI) for chronic total occlusions (CTO).
BACKGROUND Percutaneous coronary intervention for CTO remains a challenge with a high incidence of
procedural failure secondary to inability to cross the occlusion with the guidewire.
METHODS Eighty-five patients who underwent unsuccessful PCI procedures of CTO (more than three
months’ duration) had a repeat attempt of recanalization with the use of pre-procedural ICL.
Patients received a weight-adjusted dose of either alteplase (tPA) (2 to 5 mg/h) or
tenecteplase (TNK) (0.5 mg/h) for a total of 8 h. The total dose of ICL therapy was infused
split between the guiding catheter and an intracoronary infusion catheter. A step-down
multivariate logistic regression analysis was completed to determine the best predictors of
procedural success. In-hospital major adverse cardiac events (MACE) including myocardial
infarction, acute reocclusion, stroke, and death, as well as bleeding complications, were also
examined.
RESULTS The procedure was successful in 46 of 85 cases (54%). Four of 85 (5%) contained dissections
that did not result in perforations, tamponade, or MACE. The incidence of groin
complications was 7 of 85 (8%) and of bleeding complications requiring transfusions was 3 of
85 (3.5%). On multivariate analysis, predictors of success were tapering morphology (odds
ratio, 15.5; 95% confidence interval, 3.73 to 63; p  0.0002) and lack of bridging collaterals
(odds ratio, 5.08; 95% confidence interval, 1.53 to 17; p  0.008).
CONCLUSIONS Intracoronary infusion of fibrin-specific thrombolytic therapy may provide a valuable and safe
option for facilitating percutaneous revascularization of CTO. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.055793–8) © 2005 by the American College of Cardiology Foundation
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4espite the introduction of novel technologies, newer
uidewires, and the tremendous advancement of technical
kills, percutaneous coronary intervention (PCI) for chronic
otal occlusion (CTO) remains a challenge in interventional
ardiology and is unsuccessful in 30% to 40% of patients
1–5). The mechanism of failure is usually secondary to the
nability to cross the occlusion with a guidewire in the
ajority of cases, whereas the inability to advance or inflate
balloon catheter accounts for only a few cases (6). On the
ther hand, successful recanalization is associated with
mproved clinical outcome, lower need of coronary bypass
urgery, and a lower cumulative rate of cardiac death and
nfarction (6). Thus, novel approaches to assist in recanali-
ation of CTO have been proposed in recent years.
Histologically, an atherosclerotic plaque is invariably
resent in CTO and multiple layers of clot occur on top of
pisodes of plaque fissuring, accounting for the complete
cclusion (7). Pre-procedural fibrin-specific intracoronary
ytic infusion (ICL) may lyse the most recent clot compo-
ent of CTO, allowing passage of the guidewire and
acilitating recanalization. We sought to examine the feasi-
From the William Beaumont Hospital, Royal Oak, Michigan.
Manuscript received March 25, 2005; revised manuscript received May 2, 2005,
ccepted May 10, 2005.ility, predictors of procedural success, and safety of fibrin-
pecific ICL before repeat PCI for CTO.
ETHODS
tudy population. The study protocol was approved by the
uman Investigation Committee, and all patients provided
ritten informed consent. Between September 1999 and
ay 2004, 85 patients with CTO in whom the initial
ttempt at recanalization was unsuccessful were treated with
CL before repeat PCI. Patients with recent coronary
cclusion (CTO within the previous three months), an
cute myocardial infarction (MI) within the previous three
onths, and contraindication for lytic therapy were
xcluded.
re-procedural lytic therapy. Patients underwent coro-
ary angiography, and a guide catheter with pre-
anufactured side holes was placed in the target vessel.
ver a guidewire, a 3-F intracoronary infusion catheter
Ultrafuse-X catheter, SciMed, Maple Grove, Minnesota)
as positioned at the face of the CTO. Patients received a
eight-adjusted infusion of either alteplase (tPA, Genen-
ech, San Francisco, California; 0.025 to 0.05 mg/kg/h; 2
g/h for weight 60 kg, 3 mg/h for weight 61 to 80 kg,
mg/h for weight 81 to 105 kg, and 5 mg/h for weight
105 kg) or a standard dose of tenecteplase (TNK) (Ge-
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Intracoronary Fibrinolysis for CTO September 6, 2005:793–8entech; 0.5 mg/h) for 8 h before PCI, with the total dose
ivided between the infusion catheter and the guide catheter
Fig. 1). The dose was divided between the guide catheter
nd the infusion catheter to prevent clot formation in the
uide catheter. Intravenous heparin was administered dur-
ng ICL to achieve activated clotting time levels between
00 and 250 s. The doses of lytic agents were derived from
revious studies using tPA and TNK in the peripheral
irculation, whereas the duration of infusion and the dose of
eparin were derived from previous studies using heparin
ith urokinase infusion before revascularization of coronary
nd peripheral occlusions. The femoral sheath, guiding
atheter, and ultrafuse catheter were securely sutured to the
kin to ensure stability and were covered with a sterile
ressing. Patient immobility during the infusion was en-
ured to minimize bleeding and groin complications, and
dequate analgesia and sedation was administrated to opti-
ize patient comfort. Patients were observed in the coro-
ary care unit during ICL infusion and were brought back
o the laboratory for attempted recanalization using stan-
ard equipment, and in select cases the Frontrunner
LuMend, Stanford, California) device was used. On their
econd visit, the sheath and catheters were exchanged and
mpiric antibiotics were given (1 g cefazolin IV; if allergic to
ephalosporins, 1 g vancomycin).
ngiographic analysis. Angiographic analysis of the target
essel was performed independently by two experienced
nterventional cardiologists. In cases of disagreement, a
hird reviewer adjudicated the findings. The following
ngiographic variables were examined: morphology of the
tump, absolute or functional occlusion, age and length of
Abbreviations and Acronyms
CTO  chronic total occlusion
ICL  intracoronary lytic therapy
MACE  major adverse cardiac events
MI  myocardial infarction
PCI  percutaneous coronary intervention
RCA  right coronary artery
TIMI  Thrombolysis In Myocardial Infarction
TNK  tenecteplase
tPA  alteplaseigure 1. An angiogram (left) showing a guiding catheter situated in the right co
atheter is advanced to the site of occlusion. The guiding catheter and Ultrafusecclusion, vessel diameter, vessel and segment of the occlu-
ion, number of diseased vessels, presence of in-stent reste-
osis, presence of moderate or severe calcification, proximal
essel tortuosity, presence of bridging and contralateral
ollaterals, and side branch at the site of occlusion. Proce-
ural variables examined were the French size, guiding
atheter, guidewire used (hydrophilic vs. non-hydrophilic),
nd mechanism of failure (inability to pass guidewire,
nability to pass balloon catheter, and inability to inflate
alloon). In-hospital major adverse cardiac events (MACE),
leeding complications, and the need for transfusion were
lso examined.
efinitions. The CTO was defined as obstruction of a
ative coronary artery with no luminal continuity and with
hrombolysis In Myocardial Infarction (TIMI) flow grade
. The duration of the occlusion had to be 3 months,
stimated from clinical events such as MI, or proven by
revious angiography. Procedural success was defined as
estoration of TIMI flow grade 3 with a residual stenosis of
50%; MACE was defined as acute reocclusion, Q-wave
nd non–Q-wave MI, urgent coronary artery bypass graft or
epeat PCI, stroke, or death. The diagnosis of Q-wave MI
as documented by the presence of new pathologic Q waves
n the electrocardiogram. Non–Q-wave MI was defined as
hree-fold increase of total creatine kinase with increase of
B fraction, without new abnormal Q waves. Bleeding
omplications included groin hematoma (of any size), gas-
rointestinal, genitourinary, retroperitoneal, or intracranial
leeding, as well as the need for transfusion.
tatistics. Statistical analysis was performed using SAS
oftware (version 6.18, SAS Institute Inc., Cary, North
arolina). Categorical variables were examined using a
earson chi-square test in all cases, except as noted when
Fisher two-sided exact test was used. Continuous
ariables were examined using the Student t test. A p
alue of 0.05 was considered statistically significant. A
tep-down multivariate logistic regression analysis was
erformed to determine the best predictors of procedural
uccess. Included in the first step were variables with p  0.1
n the univariate analysis, and included bridging collaterals,
resence of single-vessel disease, and tapering morphology of
he occlusion.ronary artery. A guidewire is advanced in the vessel and a 3-F Ultrafuse-X
-X catheter (right) are sutured to the skin and covered in a sterile fashion.
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linical characteristics. Baseline clinical characteristics of
he patients are shown in Table 1. The majority of patients
ad a history of hypertension, 63 of 85 (74%); hyperlipid-
mia, 75 of 85 (88%); multivessel disease, 72 of 85 (85%);
jection fraction (EF)50%, 31 of 54 (57%); and presented
ith progressive symptoms of angina (angina class 2), 70
f 85 (82%).
ngiographic characteristics. The angiographic features
f most CTO were unfavorable, and in 3 of 85 (4%) cases,
he lesion length could not be estimated. All CTO were3
onths in duration; 16 were 3 to 6 months old, 16 were 6
o 12 months old, and the remainder (53 CTO) were more
han 12 months old. The majority of occlusions were in the
ight coronary artery (RCA), 53 of 85 (62%); 15 mm in
ength, 62 of 82 (73%); abrupt morphology, 64 of 85 (75%);
nd with a side branch at the area of occlusion, 51 of 85
60%). There were 14 occlusions with small side branches
1 mm), 16 occlusions with moderate-sized size branches
1 to 2 mm), and 21 occlusions with large side branches (2
m). The majority were in the proximal and mid vessel (60
f 85, 76%), but there were no ostial CTOs in this series.
nitial versus repeat PCI: technical factors. INSTITU-
ION, OPERATORS, AND PROCEDURAL DURATION. The ini-
ial PCI attempt was made at our institution in 60 of 85
rocedures. In these cases, the repeat PCI was performed by
he same operator in all but three procedures. There were
ight different operators involved in the study. Data on the
nitial procedure was available in only these 60 procedures
erformed at our institution. The initial and repeat proce-
ural durations and fluoroscopy times are shown in Table 2.
he procedural duration of the repeat PCI attempt in the 60
atients whose initial procedure was performed at our
nstitution was a mean of 64  28 min and a median of 61
in, and the fluoroscopy time was 23  12 min with a
edian of 21 min. The initial and repeat failed procedures
ere aborted if the procedural duration was 55 to 60 min,
nd/or the fluoroscopy time was15 to 20 min, and/or four
ifferent guidewires were used, and/or complications
ccurred.
able 1. Baseline Clinical Characteristics of All Patients
eceiving ICL
ICL (n  85)
ge (mean  SD) 62  11
emale 15 (18%)
ypertension 63 (74%)
iabetes 19 (22%)
yperlipidemia 75 (88%)
urrent smoker 12 (14%)
revious MI 37 (44%)
revious CABG 24 (28%)
ultivessel disease 72 (85%)
jection fraction 50% 31/54 (57%)
ngina class 2 70 (82%)T
ABG  coronary artery bypass grafting; ICL  intracoronary lytic therapy; MI 
yocardial infarction.ercutaneous coronary intervention. INITIAL PCI. The
ires used in the initial procedure were similar to those used
n the repeat attempt and are shown in Table 2. None of the
ovel Japanese guidewires were used, and the Frontrunner
as attempted in four cases. All failures were caused by the
nability to cross the CTO with the guidewire.
EPEAT PCI. The repeat PCI was performed within six
onths in 86% of patients, the remainder was performed
wo years and beyond. The procedure was successful in 46 of
5 cases (54%). There was no difference in the procedural
uccess in the first 42 procedures performed between
eptember 1999 and February 2003 and the last 43 patients
erformed between February 2003 and May 2004 (23 of 42,
5%; vs. 23 of 53, 53%, respectively; p  0.91). Of the 85
atients studied, 61 patients received tPA and 24 received
NK. A 7-F guide catheter with side holes was used in 59
f 85 (70%) cases, whereas an 8-F system was used in the
emaining cases. Simultaneous contralateral injections were
sed in five cases (two failures and three successes), where a
-F diagnostic catheter was used to engage the non-target
CI vessel for visualization of contralateral collaterals and
he distal target vessel. There were six cases of in-stent
estenosis (four failures and two successes). The same wires
ere used in the repeat attempt except for the use of the
ovel Japanese guidewires (Asahi and Miracle Bros.) in two
ases. The wires successful in crossing the CTO included
he Soft Reflex (Cordis, Johnson & Johnson, Miami Lakes,
lorida) (16 cases), Whisper (Guidant, Santa Clara, Cali-
ornia) (11 cases), Cross IT (Guidant) (7 cases), Gold Glide
Boston Scientific, SciMed, Natick, Massachusetts) (3
ases), Standard Reflex (Cordis, Johnson & Johnson) (2
ases), and the Miracle Bros. (Abbot Vascular, Santa Fe
prings, California) (1 case). Successful recanalization oc-
urred after the use of one to four of this group of
uidewires. The Frontrunner (LuMend, Stanford, Califor-
ia) was optionally used at the operator’s discretion in 15 of
5 cases (18%) after the use of at least two different wires
nd 15 min of fluoroscopy. It was successful in crossing the
TO in 4 of 15 (27%) cases. The time until crossing the
TO was (mean 34 17 min, median 32 min). Among the
ailed procedures, inability to cross the occlusion with a
uidewire was the primary cause of failure in 38 of 39 (97%).
rocedural outcome and in-hospital complications.
here were 4 of 85 (5%) contained dissections that did not
esult in perforations or tamponade. There were no major
dverse cardiac events. The incidence of groin hematomas
as 7 of 85 (8%), and incidence of bleeding complications
equiring blood transfusions was 3 of 85 (3.5%). Only four
atients (5%) had elevations in the total creatine kinase with
ncrease of MB fraction, which were all less than a three-
old increase from baseline.
TO angiographic characteristics and procedural success.
nivariate analysis of angiographic and procedural variables
n the successful group and the failure group is shown in
able 3. On multivariate analysis, predictors of successful
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Intracoronary Fibrinolysis for CTO September 6, 2005:793–8epeat PCI after ICL were tapering morphology (odds ratio,
5.5; 95% confidence interval, 3.73 to 63; p  0.0002), and
ack of bridging collaterals (odds ratio, 5.08; 95% confidence
nterval, 1.53 to 17; p  0.008) (Fig. 2). Images before and
fter PCI for CTO of the RCA are shown in Figure 3.
ISCUSSION
ecanalization of CTO is associated with a lower incidence
f cardiac deaths or MI, reduced need for bypass surgery,
nd improved anginal class in the majority of patients (6).
redictors of successful revascularization have been de-
cribed in multiple studies based on single-center experience
1–5,8–13). More recently, a multicenter randomized trial
onducted in Europe concluded that occlusion length and
uration, the presence of moderate to severe calcifications,
nd multivessel disease predicted procedural failure (6).
iven the favorable outcomes, novel mechanisms that
nhance the success of revascularization may have far-
eaching clinical benefits. This study examines the safety
nd feasibility of ICL in patients with previously unsuccess-
ul attempts of recanalization of CTO. Infusion of intra-
oronary lytic agents before a repeat attempt at recanaliza-
ion was associated with success in 50% of cases. Because
nitial PCI for CTO is only successful in 60% to 70% of
ases (1–5) and the majority of patients in this study had
ngiographically unfavorable morphology, this additional
able 2. Initial Versus Repeat PCI: Technical Factors
In
rocedure duration in min, mean  SD (median) 57
luoroscopy duration in min, mean  SD (median) 16
ires used Soft Reflex,† Ch
Whisper,‡ Go
Pilot,‡ and St
rontrunner used (n)
Boston Scientific, SciMed; †Cordis, Johnson & Johnson; ‡Guidant; §Abott Vascular.
able 3. Univariate Analysis of the Angiographic Characteristics
f All Patients Receiving ICL
Failure
(n  39)
Success
(n  46) p Value
essel
RCA 25 (64%) 28 (61%) 0.76
LAD 7 (18%) 10 (22%) 0.66
LCX 4 (10%) 4 (9%) 1.00
esion length 15 mm 33/37 (89%) 38/45 (84%) 0.75
essel diameter 3 mm 35 (90%) 42 (91%) 1.00
apering morphology 4 (10.3%) 22 (47.8%) 0.0002
ridging collaterals 19 (49%) 14 (30%) 0.085
ontralateral collaterals 18 (46%) 26 (57%) 0.34
ide branch at site of
occlusion
25 (64%) 26 (57%) 0.48
oderate or severe
calcification
8 (21%) 16 (35%) 0.15
roximal vessel tortuosity 11 (28%) 7 (15%) 0.14
istal location 8 (21%) 12 (26%) 0.55t
p
CL  intracoronary lytic therapy; LAD  left anterior descending artery; LCX 
eft circumflex; RCA  right coronary artery.uccess is extremely promising. In addition, the incidence of
ACE, bleeding complications, and need for transfusion
as minimal. The multivariate angiographic predictors of
rocedural success in this group of patients were tapering
orphology and lack of bridging collaterals.
omparison with previous CTO studies. Previous stud-
es have shown various predictors of successful recanaliza-
ion of CTO. These have included tapering morphology,
horter occlusion length and duration, single-vessel disease,
eft anterior descending artery CTO, absence of side
ranches and bridging collaterals, proximal vessel tortuosity,
nd moderate to severe calcifications (1–6). However, the
efinition of CTO varies widely among these studies, and
ubsequently the predictors of successful PCI. Our study
ncluded CTO with many of the unfavorable angiographic
haracteristics reported in these studies. There are no
tudies that have reported the predictors of successful
eattempt at revascularization of CTO after initial failure.
hus, we believe that our study reaffirms the importance of
apering morphology and lack of bridging collaterals as
redictors of procedural success for PCI of CTO, even in
epeat attempts after an initial failed procedure and with the
se of ICL.
omparison with previous studies of lytic infusion. Pre-
ious studies have examined the use of urokinase infusion of
hronic occlusions of recanalization of peripheral arteries
14), saphenous vein bypass grafts (15), and native coronary
rteries (16,17). The infusion of fibrin-specific thrombolytic
herapy in peripheral arterial occlusions for clot lysis has
een reported at doses and durations similar to those used in
igure 2. Multivariate predictors of successful recanalization of chronic
CI Repeat PCI
(51) 68  28 (64)
15) 23  11 (21)
PT,* Cross IT,‡
lide,* Shinobi,†
d Reflex†
Soft Reflex,† Choice PT,* Cross IT,‡ Whisper,‡
Gold Glide,* Shinobi,† Pilot,‡ Standard
Reflex,† Confianza,§ and Miracle Bros.§
15itial P
 28
 9 (
oice
ld G
andar
4otal occlusion with intracoronary lytic therapy infusion in patients with
revious failed attempts. CI  confidence interval.
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September 6, 2005:793–8 Intracoronary Fibrinolysis for CTOur study (18–20). Their use in native coronary arteries has
ot been reported, and in this study was associated with
imilar procedural success to urokinase and a lower inci-
ence of groin hematoma. The success rate of urokinase
nfusion in previously failed PCI for CTO was 53% (17).
owever, the presence of large side branch and/or bridging
ollaterals was excluded in that study, and the predictors of
rocedural success were not adequately described. There
ere three different protocols for urokinase infusion
100,000, 200,000, and 400,000 IU/h for 8 h. With uroki-
ase, the incidence of bleeding complications depended on
he dose of urokinase as follows: groin hematomas (35%,
3%, and 60%, respectively), bleeding complications (groin
leeding requiring transfusion, gastrointestinal, and genito-
rinary bleeding; 4%, 24%, and 25%, respectively), and
leeding complications requiring transfusion (0%, 15%, and
%, respectively) (17). The doses of fibrin-specific agents
sed in this study are equivalent to urokinase infusion of
25,000 to 200,000 U/h and seem to be associated with the
ame incidence of bleeding complications and need for
ransfusion as the previous study in the groups receiving a
ow- to medium-dose urokinase infusion. However, the
ower incidence of groin hematomas can not be explained.
imilar to their use in the peripheral circulation (18), it is
ikely that higher doses of fibrin-specific agents would lead
o higher bleeding complications similar to those of high-
ose urokinase, with no additional procedural success.
echanism of action. Primary atherosclerotic disease de-
elops over years to decades, and the plaque is invariably
resent in de novo occlusions as a minor or major part of the
uminal obstruction. Occlusive or non-occlusive, single or
ultiple layers of clot of various ages then occur on top of
pisodes of plaque fissuring, and the most recent clot
ccounts for the complete occlusion. Microchannels may
orm within the occluded segment, and together with
ilation of the vasa vasorum and clot lysis may account for
he presence of antegrade flow manifested as functional
cclusion. Successful PCI requires crossing through the clot
nd/or the microchannels (7). Fibrin-specific lytic therapy
ay lyse the most recent clot component of CTO and thus
elp “soften” the plaque, allowing passage of the guidewire.
igure 3. Angiographic images before (left) and after (right) percutaneous
he chronic total occlusion angiographic characteristics include tapering,
ocation, and no calcification. A total of three drug-eluting stents were im
nd 3.5  23) and a 4.0 non-compliant balloon was used for further expahe positioning of the intracoronary ultrafuse catheter at uhe site of the occlusion allows delivery of lytic therapy in
lose proximity to the intracoronary clot. As shown in this
tudy, this may be facilitated by the presence of a tapering
orphology that allows “wedging” of the catheter. In
ddition, absence of bridging collaterals prevents dilution of
he dose of administered lytic therapy at the desired site.
he majority of our cases were performed in the proximal
nd mid RCA CTO. We believe that the RCA is more
atulous and has fewer branching points proximally, and
hus may contain a higher clot burden in the CTO, which
ould be more responsive to lytic therapy than in left
oronary occlusions. Moreover, because of a separate ostium
nd fewer side branches proximally, a higher lytic dose may
e delivered through the guide catheter. However, the type
f vessel was not a predictor of procedural success in our
tudy and further studies may be required to validate this
ypothesis.
tudy limitations. Data on the initial procedure were
resent in only 60 of 85 patients. This affects our knowledge
f technical factors involved in this procedure. These data
re difficult to obtain because some of these procedures were
erformed more than five years ago. However, the majority
f patients underwent failed prior attempts as designated by
igh-volume experienced operators at our institution.
oreover, neither the procedural and fluoroscopy time, nor
he number and types of wires used were different between
ailure in the first and second attempts, reflecting the lack of
ajor technical differences between the initial and failed
ttempts in the majority of the procedures.
The results of the study may have been influenced by
election criteria and operator experience. Therefore, they
ay not be fully reproducible under different conditions. By
efinition, only patients who had failed previous PCI were
nrolled, and thus ICL was not compared with placebo. In
heory, attempts to recanalize the vessel may have been
ore aggressive on the second attempt, after ICL admin-
stration, and may account for the additional success rate.
oreover, the administration of heparin may have contrib-
ted to recanalization.
The optimal time for using this technique after a failed
ttempt, especially that causing a significant dissection, is
ary intervention of the chronic total occlusion of the right coronary artery.
of bridging collaterals and side branch at the area of occlusion, proximal
d in an overlapping fashion from distal to proximal (3.5  33, 3.5  33,
of the proximal stent.coron
lack
plantenknown. However, we propose a period of four to six
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Intracoronary Fibrinolysis for CTO September 6, 2005:793–8eeks after the initial PCI to help heal the dissection.
urther studies randomizing ICL to standard PCI in initial
evascularization attempts may be necessary.
The sample size of 85 patients was small, and larger
tudies are required. However, the procedural success and
elative safety of this technique makes it a valuable option in
atients with continued symptoms in whom the primary
ttempt fails. A multicenter randomized study is planned in
he upcoming two years to further study this technique. The
esults of this study will help provide answers to many of the
ypotheses suggested in our study.
onclusions. This study reports the largest series of ICL to
acilitate recanalization of CTO in patients with progressive
ymptoms in whom prior attempts failed. A high success rate
ith a low incidence of complications was observed with the
se of fibrin-specific lytic agents as compared with previous
tudies of urokinase. Delivery of an adequate dose of ICL is
ssential and is enhanced by a tapering morphology of the
cclusion and the lack of bridging collaterals; ICL should be
onsidered a valuable tool in the management of CTO.
eprint requests and correspondence: Dr. William W. O’Neill,
ivision of Cardiology, William Beaumont Hospital, 3601 West
3 Mile Road, Royal Oak, Michigan 48073. E-mail: woneill@
eaumont.edu.
EFERENCES
1. Safian RD, McCabe CH, Sipperly ME, McKay RG, Baim DS. Initial
success and long-term follow-up of percutaneous transluminal coro-
nary angioplasty in chronic total occlusions versus conventional steno-
ses. Am J Cardiol 1988;61:23G–8G.
2. Bell MR, Berger PB, Bresnahan JF, Reeder GS, Bailey KR, Holmes DR Jr.
Initial and long-term outcome of 354 patients after coronary balloon angio-
plasty of total coronary artery occlusions. Circulation 1992;85:1003–11.
3. Ruocco NA Jr., Ring ME, Holubkov R, Jacobs AK, Detre KM, Faxon
DP. Results of coronary angioplasty of chronic total occlusions (the
National Heart, Lung, and Blood Institute 1985–1986 Percutaneous
Transluminal Angioplasty Registry). Am J Cardiol 1992;69:69–76.
4. Ivanhoe RJ,WeintraubWS,Douglas JS Jr., et al. Percutaneous transluminal
coronary angioplasty of chronic total occlusions. Primary success, restenosis,
and long-term clinical follow-up. Circulation 1992;85:106–15.
5. Maiello L, Colombo A, Gianrossi R, et al. Coronary angioplasty of
chronic occlusions: factors predictive of procedural success. Am
Heart J 1992;124:581–4.6. Olivari Z, Rubertelli P, Piscione F, et al., TOASR-GISE Investiga-
tors. Immediate results and one-year clinical outcome after percuta-
neous coronary interventions in chronic total occlusions: data from a
multicenter, prospective, observational study (TOAST-GISE). J Am
Coll Cardiol 2003;41:1672–8.
7. Meier B. Chronic total occlusions. In: Topol EJ, editor. Text Book of
Interventional Cardiology. 4th edition. Philadelphia, PA: Saunders,
2003:303–16.
8. Hamm CW, Kupper W, Kuck KH, Hofmann D, Bleifeld W.
Recanalization of chronic, totally occluded coronary arteries by new
angioplasty systems. Am J Cardiol 1990;66:1459–63.
9. Stone GW, Rutherford BD, McConahay DR, et al. Procedural
outcome of angioplasty for total coronary artery occlusion: an analysis
of 971 lesions in 905 patients. J Am Coll Cardiol 1990;15:849–56.
0. Tan KH, Sulke N, Taub NA, Watts E, Karani S, Sowton E.
Determinants of success of coronary angioplasty in patients with a
chronic total occlusion: a multiple logistic regression model to improve
selection of patients. Br Heart J 1993;70:126–31.
1. Ishizaka N, Issiki T, Saeki F, et al. Angiographic follow-up after successful
percutaneous coronary angioplasty for chronic total coronary occlusion:
experience in 110 consecutive patients. Am Heart J 1994;127:8–12.
2. Kinoshita I, Katoh O, Nariyama J, et al. Coronary angioplasty of
chronic total occlusions with bridging collateral vessels: immediate and
follow-up outcome from a large single-center experience. J Am Coll
Cardiol 1995;26:409–15.
3. Angioi M, Danchin N, Juilliere Y, et al. Is percutaneous transluminal
coronary angioplasty in chronic total coronary occlusion justified?
Long term results in a series of 201 patients. Arch Mal Coeur Vaiss
1995;88:1383–9.
4. Cragg AH, Smith TP, Corson JD, et al. Two urokinase dosing
regimens in native arterial and graft occlusions: initial results of a
prospective randomized clinical trial. Radiology 1991;178:681–6.
5. Hartmann JR, McKeever LS, Stamato NJ, et al. Recanalization of
chronically occluded aortocoronary saphenous vein bypass grafts by
extended infusion of urokinase: initial result and short-term follow-up.
J Am Coll Cardiol 1991;18:1517–23.
6. Ajluni SC, Jones D, Zidar FJ, et al. Prolonged urokinase infusion for
chronic total native coronary artery occlusions: clinical, angiographic, and
treatment observations. Cathter Cardiovasc Diagn 1995;34:106–10.
7. Zidar FJ, Kaplan BM, O’Neill WW, et al. Prospective randomized
trial of prolonged intracoronary urokinase infusion for chronic total
occlusions in native arteries. J Am Coll Cardiol 1996;27:1406–12.
8. Semba CP, Murphy TP, Bakal CW, Calis KA, Matalon TA.
Thrombolytic therapy with use of alteplase (rt-PA) in peripheral
arterial occlusive disease: review of the clinical literature. The Advisory
Panel. J Vasc Interv Radiol 2000;11:149–61.
9. Burkart DJ, Borsa JJ, Anthony JP, Thurlo SR. Thrombolysis of acute
peripheral arterial and venous occlusions with tenecteplase and eptifi-
batide: a pilot study. J Vasc Interv Radiol 2003;14:729–33.
0. Razavi MK, Wong H, Kee ST, Sze DY, Semba CP, Dake MD. Initial
clinical results of tenecteplase (TNK) in catheter-directed thrombo-
lytic therapy. J Endovasc Ther 2002;9:593–8.
